Summary Arterial hypertension and poor glycaemic control are central to the development of microalbuminuria in insulin-dependent diabetes mellitus (IDDM). Recent consensus has established sensitive criteria for their detection and treatment, although the proportion of patients who may benefit is unclear. Between 1988 and 1990, we measured urinary albumin to creatinine concentration ratio (A/C) in 3,636 adult out-patients with IDDM of more than 3 years duration, serum creatinine under 133 vmol/1 and who were not undergoing antihypertensive treatment. A/C indicating microalbuminuria (_> 2.38/ 2.96 mg/mmol, male/female) was found in 620 of 3,451 patients without proteinuria, and associated with hypertension (blood pressure >_ 140 and/or 90 mmHg; p = 0.0016; rate: 39.6 %), independent of diabetes duration (p =0.0082) and male gender (p = 0.0350; relative risk = 1.16; 95 % confidence interval: 1.01-1.32). Hypertension was less common among those with normal A/C (27.5 %, p < 0.0001) but was positively related with diabetes duration. Of the 1,015 patients with A/C >_ 2.0 mg/mmol 529 were reexamined. Glycated haemoglobin levels exceeded 3 SD above the mean of normal in 84.3 % of the 198 microalbuminuric patients (AER=20-200 ~tg/min), but were comparably poor (79.2 %) in normoalbuminuria. Duration of diabetes was inversely related to glycated haemoglobin only in microalbuminuria (0.05 < p < 0.1). Intervention to lower blood pressure remains mainly restricted to those patients with long-term diabetes and slower development of kidney disease. Near-normalisation of glycaemia remains the priority for the majority of patients with microalbuminuria. [Diabetologia (1994[Diabetologia ( ) 37: 1015[Diabetologia ( -1024 Key words Insulin-dependent diabetes mellitus, arterial hypertension, borderline hypertension, microalbuminuria, diabetic nephropathy.
end-stage renal failure and renal replacement therapy. IDDM is characterised by a high rate of cardiovascular morbidity and mortality, which is predominantly explained by the subset of patients with renal disease [3, 4] . The biological mechanisms underlying the association of proteinuria with cardiovascular events are still unclear, but arterial hypertension is an established risk factor for cardiorenal mortality among long-term IDDM patients [5] , and both the course of kidney disease and mortality can benefit from near-normalisation of blood pressure following pharmacological intervention at the stage of clinical nephropathy [6] [7] [8] .
Although blood pressure levels are often within the World Health Organisation criteria for arterial hypertension among diabetic patients without proteinuria [9] [10] [11] [12] , sub-clinical increases in blood pressure can predict the onset of clinical proteinuria [13, 14] , perhaps in parallel with microalbuminuria [15] [16] [17] [18] [19] , and their pharmacologic correction is known to slow the progression of microalbuminuria [20, 21] . The recent extension of detection and treatment criteria for arterial hypertension to include diabetic patients with borderline hypertension [22] may be particularly relevant to those with microalbuminuria [23] .
The proportion of either risk factor is unclear in Mediterranean countries, and studies of the prevalence of hypertension and microalbuminuria in large groups of patients with IDDM have never considered borderline hypertension [9] [10] [11] . Metabolic abnormalities are another established factor in the progression of microalbuminuria [14, [24] [25] [26] , and sensitive criteria for the detection of poor glycaemic control are likewise recommended in the secondary prevention of diabetic nephropathy [23] , although the proportion of patients who may benefit from nearnormalising glycaemia in ordinary clinical practice is likewise unclear. We therefore decided to study arterial hypertension and microalbuminuria in IDDM, and examined the cross-sectional relationship of microalbuminuria with blood pressure and glycaemic control.
Patients and methods

Study design.
Assuming that there is a lower incidence of microalbuminuria in a Mediterranean country than in England, as found in a preliminary report which suggested a rate of 5.7 % [27], we studied a group of more than 3,000 patients with IDDM which was considered adequate to identify at least 100 patients with microalbuminuria. The study was designed as a cross-sectional multi-centre screening in two phases, with a standardised collection of clinical and chemical data from independent observers and laboratories. There were no geographic criteria in the choice of the distribution of centres [28] . Tertiary referral centres co-ordinated the ac-R. Mangili et al.: Hypertension and microalbuminuria tivity of the secondary referral centres located in the same region, equally selecting patients on a secondary referral basis.
Selection criteria.
Patients were selected at phase 1 to attend one of the participating diabetes outpatient clinics for at least 6 months following the first visit. Informed consent was verbally obtained from all patients, who had diabetes for more than 3 years, between the ages of 16-65 years, with known serum creatinine less than 133 ~tmol/1 (1.5 mg/dl), and absence of persistent urinary sediment abnormalities and/or non-diabetic kidney disease. At this stage, basic demographics, antihypertensive treatment, serum creatinine concentration, and blood pressure were measured and recorded. A single non-timed urine sample was obtained from each patient to measure A/C, and indicate the presence of microalbuminuria. Local observers had no knowledge of current urinary albumin excretion, which had not been routinely tested at most of the secondary referral centres at the time of the study (1988) (1989) (1990) .
Of the 3,988 patients meeting the above criteria, 352 were being treated for hypertension ( Fig. 1 ) and were therefore excluded, because of the confusing effect of antihypertensive treatment upon AER and on the natural course of diabetic kidney disease. Of the remaining 3,636 patients, only those with A/C over 2.0 mg/mmol were subsequently considered for phase 2 evaluation, although only 529 patients (52.1%) submitted three consecutive timed overnight urine collections for the measurement of AER. Comparisons of their clinical features at phase i with those of the patients who failed to complete the study suggested similarities in duration of diabetes (16.8 + 8.8 vs 16.9 + 8.1 years, p = NS), A/C (6.6 x/+ 2.8 vs 7.2 x/+ 3.3 mg/mmol, geometric mean x/+ tolerance factor, p = NS) and proportion of male patients (52.4 vs 51.8 %, p = NS), but patients who completed the study were younger (39 On the second visit, body weight and height were measured and recorded along with blood pressure and total daily insulin. Blood was taken for measurement of glycated haemoglobin, blood glucose and serum creatinine, while the patients were in the fasting state.
Clinical and laboratory methods. Single blood pressure recordings (Korotkoff phases I/V) to the nearest 5 mm Hg were taken on each visit after 5-rain rest with an ordinary mercury sphygmomanometer, with appropriately sized cuffs. Body weight was obtained in light indoor clothing, and height was measured with no shoes. Body mass index was calculated and expressed in kg/m 2. Single void, non-timed urine samples were collected with no preservative added. Timed overnight urine samples were collected in bottles with preservative (Thimerosal, Sigma Chemical Co., St. Louis, MO, USA; 500 ~1 of a i g/1 solution per bottle; and NaOH, 500 ~1 of a 4 mol/1 solution per bottle). All urine samples were aliquoted and stored at -20 ~ or less until analysis. The measurements of UAlb (RIA; either Pharmacia, Uppsala, Sweden; or SCLAVO, Cinisello Balsamo, Italy) and urinary creatinine (Jaff6 reaction) [29] were centralised by region, with a total of nine laboratories. The inter-laboratory coefficient of variation in UAlb, as evaluated by an external quality control programme, was 40 % around 3.4 mg/1, but less than 15 % at concentrations in the microalbuminuric range was acceptable [30] . The variability in the measurement of urinary creatinine concentration was comparable with the preliminary stage of the study [28] . Serum creatinine and blood glucose (routine enzymatic-colorimetric methods) were likewise centralised at the same laboratories. Glycated haemoglobin was measured locally, and depended on HbA I or HbAic determinations; data were then individually readjusted to the local mean and SD of normal, and expressed in number of SD above the mean of normal [23] .
Diagnostic criteria. The diagnosis of IDDM was established by the presence of insulin-treated, ketosis-prone diabetes with onset before the age of 40 years. Poor glycaemic control was defined as glycated haemoglobin levels more than 3 SD above the mean of normal [23] . The diagnosis of arterial hypertension was consistent with WHO criteria, but normal blood pressure was restricted to the patients with systolic/diastolic recordings less than 140 and 90 mmHg, respectively, to comply with recent consensus [23] . The finding of AER in the range of 20-200 ~g/min in at least two out of three sterile (nitriteand leucocyte-dipstick negative) collections established the presence of microalbuminuria. For the purpose of statistical analysis, albuminuria measurements obtained during study phase I were categorised by the use of UAlb and A/C levels as previously stated [28] . In line with the traditional use of concentration (dipstick-reagent) tests for the diagnosis of clinical proteinuria, UAlb over 150 rag/1 was used to suggest the presence of AER over 200~tg/min. Among the patients with lower UAlb, A/ C _> 2.38/2.96 rag/retool (male/female) was assumed to detect AER higher than 20 lxg/min with 77 % sensitivity and 78 % positive predictive value. As more than 20 % of the patients with microalbuminuria have A/C less than the above levels, a borderline range was considered, and A/C under 1.20/ 1.52 mg/mmol (male/female) was taken to suggest AER under 20 ~tg/min with a predictive value over 99 %.
Statistical analysis
Data were analysed by the use of commercial software packages (SAS and JMP; SAS Institute Inc., Cary, NC, USA), and are presented as arithmetic mean with SD or rates with 95 % C.I. Variables deviating from the normal distribution (significant Kolmogorov-Smirnov-Lilliefors or Wilks-Shapiro test, according to a sample size of larger or smaller than 2000) were conservatively rank-averaged before analysis, as appropriate. Differences between groups were addressed by one-way analysis of variance, allowing for unequal variance according to Welch, and significance was adjusted for multiple comparisons by the Tuckey-Kramer test. Simple relationships between categorical effects were addressed by contingency table analysis. Multiple regression, analysis of covariance and logistic models were addressed by the general linear models procedure after rank-transformation of all continuously distributed variables. Reports include the number of df due to model and effect components, which are directly relevant to chi squarebased analyses. The dfdue to error, as relevant to F Ratio statistics, can be obtained by [n -(1 + dr)], where n is the total number of observations. As statistical associations were similar before and after rank-transformation the usual parametric analyses were chosen for model presentation, with beta-coefficients indicating the change in the dependent variable per unit increase of the independent variable. The null hypothesis was rejected for two-tailed p levels below 5 %.
Results
Study phase 1. Raised UAlb and A/C levels, respectively, suggesting the presence of AER in the macroand microalbuminuric range, were found for all diabetes durations, both among male and female patients (Table 1) . Male gender and duration of diabetes were positively associated with greater probability of UAlb >_ 150 rag/1 (n = 3636; whole model R 2 = 0.028, p < 0.0001; gender: p = 0.0051; duration of diabetes: p < 0.0001) and A/C in the range of microalbuminuria among those with UAlb < 150 rag/1 (n = 3451; whole modelR 2 = 0.014,p < 0.0001; gender:p = 0.0098; duration of diabetes: p < 0.0001), although the raw relative risk for men was just above 1 both for the presence of UAlb > 150 mg/1 (1.48; 95 % C.I. = 1.09-2.00) and for the presence of A/C in the microalbuminuric range (1.16; 95% C.I. = 1.01-1.32). Details of the clinical features of patients at phase i were also consistent with parallel associations of raised urinary albumin with older age and higher blood pressures, with arterial and borderline hypertension together characterising up to 40 % of the patients with A/C in the microalbuminuric range (Table 2) .
Among the patients with UAlb less than 150 mg/I, having A/C in the microalbuminuric range remained independently related to hypertension (p = 0.0016), male gender (p = 0.0350), and duration of diabetes (p = 0.0082) weighing for the effects of age (p = NS) and laboratory of measurement (p < 0.0001) in a multiple logistic regression model (n = 3451; whole model R 2 = 0.026, p < 0.0001). Comparable rates of hypertension were present, however, among those with borderline A/C (Table 2) . Table 3 shows unadjusted rates of hypertension by duration of diabetes and A/ C levels. Linear models reciprocally addressing the concomitants of systolic and diastolic blood pressure reconfirmed a positive and significant effect of A/C among the patients with UAlb < 150 mg/1 independent of the parallel associations of blood pressures with age and male gender (Table 4) . There was also an independent relationship between systolic blood pressure and diabetes duration.
Study phase 2.
Of the 529 patients who completed the study, 47 had macroalbuminuria and 198 had microalbuminuria, yielding a proportionally recalculated rate of microalbuminuria of 10.7 % out of the nonmacroalbuminuric patients, which did not account for the 89 % sensitivity of the screening technique [28] .
Comparisons of their clinical features with the 284 patients who turned normoalbuminuric reconfirmed the above described associations of raised AER with older age, male gender, longer duration of diabetes and higher blood pressure (Table 5) . Rates of arterial and borderline hypertension approximated phase 1 findings in the corresponding subsets. In addition, AER was paralleled by small but significant differences in body mass index and serum creatinine, whereas differences in daily insulin dose, blood glucose and glycated haemoglobin levels were not significant. Likewise, poor glycaemic control characterised a majority of the patients in both groups.
Simple regression analyses indicated that among the patients with microalbuminuria there were borderline inverse relationships of diabetes duration Multiple regression analyses suggested that blood pressure was independently associated with diabetes duration only among those patients with microalbuminuria, whereas age and body mass index were the main concomitants of systolic and diastolic blood pressure in the subset of normoalbuminuric patients, also after allowing more variables of putative relevance to blood pressure in the statistical models (Table 6).
Discussion
This study reports the rates of microalbuminuria in a large group of IDDM outpatients without clinical proteinuria, addressing for the first time the proportion of these patients who may be candidates for antihypertensive treatment and near-normalisation of glycaemic control [22, 23] . Furthermore, analyses of the concomitants of raised urinary albumin agree with known positive and independent associations with male gender [1, 9, 11, 12, 31, 32] , duration of diabetes [9, 11] and blood pressure [9] [10] [11] [12] 33] .
In contrast with an initial screening estimate of 17.9 % from A/C of single random urine samples, the recalculated rate of microalbuminuria was only 10.7 % after multiple measurements of AER in overnight collections. However, both the incomplete sensitivity of the operative A/C cut-off level [28] and the clinical features of the patients who were re-examined were consistent with a negative selection bias during the second phase of the study. Also, daytime increases in albumin excretion [34] , reflecting the acute effects of dietary protein intake [35] and Table 6 . Study phase 2. Linear models examining the concomitants of systolic and diastolic blood pressure among IDDM patients with microalbuminuria (n = 198) and among t-. [36] , may parallel the above difference. A/C is not an alternative to AER in the diagnosis of microalbuminuria, but our use of independent A/C levels which are known to detect AER above 20 ~tg/min with identical sensitivity and positive predictive value [28] may minimise the bias in the calculation of the expected rates. Our initial patients were not selected to represent all of those with a clinical record at participating clinics, as other studies have done [9] [10] [11] . It has been shown that if recruitment is made from patients attending the clinic twice per year, there is a lower chance of selecting patients with complications [2, 37] . Under these assumptions, a 17.9 % rate may be more representative, and comparable with a 14.9% estimate from Denmark [10] , but remains less than the initial finding of a 27 % prevalence also from Denmark [9] . A considerably lower rate of 3.7 % was reported by the Microalbuminuria Collaborative Study Group [11] , by re-examination of patients initially selected by less sensitive criteria, and with the restriction of the diagnosis of microalbuminuria to AER above 30 ~g/min. Interestingly, about 11% of the patients with a short duration of diabetes may have microalbuminuric A/C levels. This was not previously considered by two studies [9, 10] and could have been missed in a smaller sample of patients [11] . However, microalbuminuria is rare at IDDM onset [38] , and our exclusion of patients with less than a 4-year duration may have positively biased our estimate.
Higher rates of microalbuminuria characterised patients later in the course of diabetes, and were not uncommon with long diabetes duration [9, 11] , when the risk of developing nephropathy might be reduced [1, 2[. The concomitants and outcome of microalbuminuria late in the course of diabetes are unclear [39] [40] [41] . Trends in the reduction of incidence of persistent proteinuria are generally assumed to parallel improvements in the standards of glycaemic control [32, 42] , and may indicate a later development of microalbuminuria [26] or persistence of the subclinical stage [24] [25] [26] . Furthermore, poor glycaemic control is a known factor of progression to [43, 44] and through the course of microalbuminuria [41] , and the trend to an inverse association of diabetes duration with glycated haemoglobin levels among our microalbuminuric patients may reflect this. Statistical modelling also suggested that blood pressures may be positively related to diabetes duration, independent of AER, only among the patients with microalbuminuria, suggesting that hypertension could be more common among those with a stow disease progression. This association was not detectable in the subset of patients who were normoalbuminuric at reexamination, where two common concomitants of hypertension, age and body mass index, were the predominant effects associated with blood pressure, and long diabetes duration could indicate protection from the risk of kidney damage [1, 2, 13] .
Interpretation of cross-sectional data should be conservative [45] , and our study excludes from detailed evaluations the normoalbuminuric patients who initially screened negative. Furthermore, neither family history of hypertension nor erythrocyte sodium-lithium countertransport activity were considered. These may be positively associated with overt nephropathy [46] [47] [48] , microalbuminuria [49, 50] and blood pressure [14, 50] in IDDM. In the single cohort study accounting for all these factors among patients with a 15-20 year diabetes duration, elevated sodium-lithium countertransport was related to higher risk of developing either nephropathy (in the presence of poor glycaemic control) or simple hypertension (with excellent glycaemic control). In contrast to the above observations, the risk of simple progression to microalbuminuria was predominantly attributed to poor glycaemic control, and not to elevated sodium-lithium countertransport, which did not reach significance [141 .
While the nature of the genetic background of nephropathy is controversial [48, 51] , our failure to associate microalbuminuria with poor glycaemic control may either parallel the above selection bias, or relate to the smaller power of cross-sectional evidence, where this relationship is likewise missed [9, 11, 51, 52] . Also, the finding that a large majority of microalbuminuric patients may be candidates for the near-normalisation of glycaemia may be of little interest after the recent results of the Diabetes Control and Complications study [26] . This clearly indicated that intensive insulin treatment is highly relevant to the primary prevention of nephropathy, with microalbuminuria being delayed by several years [26] . Intensive insulin treatment can also delay the onset of diabetic retinal and neural abnormalities, thus encouraging early and aggressive correction of hyperglycaemia, irrespective of complications being present [26] . However, the incidence of microalbuminuria could not be entirely suppressed, and the target of near-normoglycaemia may not be feasible in all the patients randomised to intensive treatment [26] . Furthermore, the benefits of treatment must be weighted against the possibility of severe hypoglycaemia, supporting the prospective use of alternative measures in the prevention of nephropathy.
In line with several other studies, only a relatively small minority of our patients with microalbuminuria would be considered for treatment according to the conservative WHO diagnosis of hypertension [9] [10] [11] [12] . Recent expansion of the criteria to include those with borderline hypertension may increase the number to 40-50 %, although a majority of these patients appear to be among those with long diabetes duration as expected [9] . Thus, current indications to treat hypertension in microalbuminuria are in favour of patients whose kidney damage follows a relatively benign course. In addition, the proportion of normoalbuminuric patients who may be considered for antihypertensive treatment following recent consensus has also considerably expanded, albeit less than in microalbuminuria. This intervention is justified in normoalbuminuria mainly because of cardiovascular considerations [22, 23] , as its relevance to the primary prevention of nephropathy is not known, and findings that raised blood pressure may anticipate microalbuminuria remain controversial [43, 44, 53] .
A majority of the patients who present microalbuminuria early in the course of diabetes are normotensive if judged by the current criteria. While the presence of microalbuminuria per se may not always indicate a fast progression to proteinuria [41] , two studies have now reported that the onset of proteinuria can be postponed by antihypertensive treatment in normotensive IDDM patients with microalbuminuria, independent of changes in glycaemic control [21, 54] . Indeed, cost-benefit ratio analyses of screening for microalbuminuria, and administration of antihypertensive treatment irrespective of blood pressure in a computer-simulated cohort of these patients, have been consistent with life-and money-saving effects [551.
In conclusion, indications to treat borderline hypertension may largely implement the secondary prevention of nephropathy, although most patients are simply candidates for near-normalisation of glycaemia. Should the benefits of systemic blood pressure reduction among normotensive patients with microalbuminuria be confirmed, it might extend to microalbuminuria per se, and add to the benefits of nearnormalising glycaemic control.
